Close Menu

structural variation analysis

The firm is offering approximately 13.8 million shares and the same number of warrants to purchase shares, which will be sold together.

Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.

The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.